Background: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer.

Patients And Methods: Serum levels of P1NP, CA 15-3 and CA 125 were analyzed using specific immunoassays. Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated.

Results: P1NP concentrations were elevated in up to 70% of patients with confirmed bone metastases. The P1NP levels were significantly higher in patients with bone metastases (median: 134 ng/ml) than in those without bone spread (median: 58.5 ng/ml).

Conclusion: Markers of biochemical bone remodeling can be used in assessing and managing patients with malignancies that metastasize to bone. These markers are abnormally raised in the blood of patients with metastatic bone disease.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients metastatic
12
amino-terminal propeptide
8
15-3 125
8
bone metastases
8
bone
7
patients
7
p1np
5
total procollagen
4
procollagen type
4
type amino-terminal
4

Similar Publications

Purpose: This paper aims to delve into the critical aspect of supplier selection in the healthcare sector, emphasizing the significance of strategic sourcing in enhancing operational efficiency and quality of services. The primary aim is to develop a comprehensive framework for supplier evaluation that aligns with the unique requirements of hospitals, ultimately improving procurement processes and patient care outcomes.

Design/methodology/approach: The study leverages the renowned Carter's 7 C model as a foundational framework for supplier assessment, supplemented by insights gathered from interviews with experts in the New Product Introduction, Purchasing and Procurement departments of a leading hospital in India.

View Article and Find Full Text PDF

Immune checkpoint inhibitors have improved the treatment of metastatic renal cell carcinoma (RCC), with the combination of nivolumab (NIVO) and ipilimumab (IPI) showing promising results. However, not all patients benefit from these therapies, emphasizing the need for reliable, easily assessable biomarkers. This multicenter study involved 116 advanced RCC patients treated with NIVO + IPI across nine oncology centers in Poland.

View Article and Find Full Text PDF

The most common cause of rotator cuff injury is supraspinatus tendon tears (STTs). High-intensity laser therapy (HILT) has recently emerged as an important conservative treatment option. This study was designed as a randomised controlled trial in patients with partial STTs to compare the effects of HILT with those of ultrasound (US) therapy.

View Article and Find Full Text PDF

Dendritic cell (DC) activation by pattern recognition receptors like Toll-like-receptors (TLRs) is crucial for cancer immunotherapies. Here, we demonstrate the effectiveness of the TLR7/8 agonist imiquimod (IMQ) in treating both local tumors and distant metastases. Administered orally, IMQ activates plasmacytoid DCs (pDCs) to produce systemic type I interferons (IFN-I) required for TLR7/8 upregulation in DCs and macrophages, sensitizing them to topical IMQ treatment, which is essential for therapeutic efficacy.

View Article and Find Full Text PDF

Predictors associated with time to default for HIV/AIDS patients under HAART at Debre Tabor Referral Hospital: a Cox regression model.

Sci Rep

January 2025

Department of Statistics, College of Natural and Computational Science, Debre Tabor University, Debre Tabor, Ethiopia.

The human immunodeficiency virus systematically undermines the immune system, which serves as our body's inherent safeguard against diseases. Currently, it is the most serious threat to public health. Ethiopia is among the countries with the highest prevalence of HIV/AIDS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!